| SNPHY Stock | | | USD 11.00 0.01 0.09% |
CFO
Kazuo Koshiji is CFO, Head of Fin. Division and Sr. Corporate Officer of Santen Pharmaceutical Co since 2017.
| Tenure | 7 years |
| Phone | 81 6 7664 8621 |
| Web | https://www.santen.com |
Santen Pharmaceutical Management Efficiency
Santen Pharmaceutical's management efficiency ratios could be used to measure how well Santen Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.
Santen Pharmaceutical Co has accumulated 32.93
B in total debt with debt to equity ratio
(D/E) of 0.1, which may suggest the company is not taking enough advantage from borrowing. Santen Pharmaceutical has a current ratio of 2.43, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Santen Pharmaceutical until it has trouble settling it off, either with new capital or with free cash flow. So, Santen Pharmaceutical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Santen Pharmaceutical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Santen to invest in growth at high rates of return. When we think about Santen Pharmaceutical's use of debt, we should always consider it together with cash and equity.
Similar Executives
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan. Santen Pharmaceutical operates under Drug ManufacturersGeneral classification in the United States and is traded on OTC Exchange. It employs 4315 people. Santen Pharmaceutical Co [SNPHY] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Santen Pharmaceutical Leadership Team
Elected by the shareholders, the Santen Pharmaceutical's board of directors comprises two types of representatives: Santen Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Santen. The board's role is to monitor Santen Pharmaceutical's management team and ensure that shareholders' interests are well served. Santen Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Santen Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Satoshi Suzuki, Executive Officer, Chief Director of Planning | |
| Nobuko Kato, Chief Officer | |
| Mika Masunari, G Officer | |
| Kazuo Koshiji, CFO, Head of Fin. Division and Sr. Corporate Officer | |
| Nikolas Tripodis, Chief Officer | |
| Kaori Itagaki, Gen Group | |
| Takeshi Ito, Executive Officer, Senior Director of Medicine Sales in Medicine Business Unit | |
| Shinichi Teramachi, Head Officer | |
| Kenji Morishima, Executive Officer, Chief Director of Human Resources & Organization Development and CSR | |
| Ippei Kurihara, Japan Department | |
| Minori Hara, Chief Officer | |
Santen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Santen Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Santen Pink Sheet Analysis
When running Santen Pharmaceutical's price analysis, check to
measure Santen Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santen Pharmaceutical is operating at the current time. Most of Santen Pharmaceutical's value examination focuses on studying past and present price action to
predict the probability of Santen Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santen Pharmaceutical's price. Additionally, you may evaluate how the addition of Santen Pharmaceutical to your portfolios can decrease your overall portfolio volatility.